Pfizer’s COVID drug data supports use in high-risk patients – FDA staff

(Reuters) -The U.S. Food and Drug Administration’s staff reviewers said on Tuesday that data from Pfizer Inc’s trials of its COVID-19 drug supports its use in adults at high-risk of the disease, ahead of a meeting of the agency’s experts to discuss full approval of the pill. Reviewers also said that analyses conducted by the regulator and Pfizer did not identify a clear association between Paxlovid and a rebound in COVID symptoms seen among some patients. The comments were made in the FDA’s briefing documents ahead of a meeting of the agency’s external advisers on Thursday. A full approval wou…

Read More